Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amphotericin B liposomal - Gilead Sciences

Next Previous
X
Search
Drug Profile

Amphotericin B liposomal - Gilead Sciences

Alternative Names: AmBisome; SM 26000; SM-26000 Injection; SMP 26000

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer Drugs for Neglected Diseases Initiative Foundation; Gilead Sciences; Knight Therapeutics; Sumitomo Pharma
  • Class Antifungals; Antiprotozoals; Antipyretics; Macrolides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cryptococcosis; Febrile neutropenia; Fever of unknown origin; Mycoses; Visceral leishmaniasis
  • Phase II Histoplasmosis
  • Discontinued Candidiasis

Most Recent Events

  • 19 Oct 2022 Phase-II clinical trials in Histoplasmosis in Brazil (IV)
  • 19 Oct 2022 Efficacy and adverse events data from a phase II trial in Histoplasmosis presented at the IDWeek 2022
  • 19 Oct 2022 Gilead plans a phase III trial for histoplasmosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top